البحث عن طبيب

Dean M. Wingerchuk, M.D.

  1. Neurologist
طلب موعد

المنشورات

  1. Cree BAC, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, She D, Rees W, Smith M, Cimbora D, Katz E, Bennett JL, N-MOmentum study investigators. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol. 2024 Jun; 23 (6):588-602
    View PubMed
  2. Carnero Contentti E, Wingerchuk DM. MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes. Mult Scler. 2024 Jan; 30 (1):19-21
    View PubMed
  3. Elsbernd P, Cacciaguerra L, Krecke KN, Chen JJ, Gritsch D, Lopez-Chiriboga AS, Sechi E, Redenbaugh V, Morris PP, Carter JL, Wingerchuk DM, Tillema JM, Valencia-Sanchez C, Thakolwiboon S, Pittock SJ, Flanagan EP. Cerebral enhancement in MOG antibody-associated disease. J Neurol Neurosurg Psychiatry. 2023 Dec 14; 95 (1):14-18
    View PubMed
  4. Majed M, Valencia Sanchez C, Bennett JL, Fryer J, Mulligan MD, Redenbaugh V, McKeon A, Mills JR, Wingerchuk DM, Lennon VA, Weinshenker B, Chen JJ, Flanagan EP, Pittock SJ, Kunchok A. Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis. Ann Neurol. 2023 Oct; 94 (4):727-735 Epub 2023 July 05
    View PubMed
  5. Aktas O, Hartung HP, Smith MA, Rees WA, Fujihara K, Paul F, Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Cutter G, She D, Gunsior M, Cimbora D, Katz E, Cree BA, N-MOmentum study investigators. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry. 2023 Sep; 94 (9):757-768 Epub 2023 May 23
    View PubMed
  6. Weinshenker BG, Wingerchuk DM, Green AJ, Bennett JL, Kim HJ, Pittock SJ, Fujihara K, Paul F, Cutter G, Marignier R, Aktas O, Hartung HP, She D, Smith M, Rees W, Patterson K, Cimbora D, Katz E, Cree BA. Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum. Mult Scler. 2023 Jul; 29 (8):945-955 Epub 2023 June 06
    View PubMed
  7. Capobianco M, Ringelstein M, Welsh C, Lobo P, deFiebre G, Lana-Peixoto M, Wang J, Min JH, Wingerchuk DM. Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews. Neurol Ther. 2023 Apr; 12 (2):635-650 Epub 2023 Feb 24
    View PubMed
  8. Min JH, Capobianco M, Welsh C, Lobo P, deFiebre G, Lana-Peixoto M, Wingerchuk DM, Wang J, Ringelstein M. Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews. Neurol Ther. 2023 Apr; 12 (2):619-633 Epub 2023 Feb 24
    View PubMed
  9. Mbonde AA, Grill MF, Harahsheh EY, Marks LA, Wingerchuk DM, O'Carroll CB. Is Intravenous Immunoglobulin Effective in Reducing the Risk of Mortality and Morbidity in Neuroinvasive West Nile Virus Infection?: A Critically Appraised Topic. Neurologist. 2023 Mar 1; 28 (2):129-134 Epub 2023 Mar 01
    View PubMed
  10. Valencia-Sanchez C, Wingerchuk DM, Dhamija R. Teaching NeuroImages: Spinal xanthomatosis: A misdiagnosed, treatable cause of progressive myelopathy. Neurology. 2023; 100 (16):S234-5
  11. Berthele A, Levy M, Wingerchuk DM, Pittock SJ, Shang S, Kielhorn A, Royston M, Sabatella G, Palace J. A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder. Front Neurol. 2023; 14:1099376 Epub 2023 Apr 11
    View PubMed
  12. Bennett JL, Aktas O, Rees WA, Smith MA, Gunsior M, Yan L, She D, Cimbora D, Pittock SJ, Weinshenker BG, Paul F, Marignier R, Wingerchuk D, Cutter G, Green A, Hartung HP, Kim HJ, Fujihara K, Levy M, Katz E, Cree BAC, N-MOmentum study investigators. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. EBioMedicine. 2022 Dec; 86:104321 Epub 2022 Nov 10
    View PubMed
  13. Wingerchuk DM, Weinshenker BG, McCormick D, Barron S, Simone L, Jarzylo L. Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder. J Manag Care Spec Pharm. 2022 Dec; 28 (12-a Suppl):S3-S27
    View PubMed
  14. Gritsch D, Mrugala MM, Marks LA, Wingerchuk DM, O'Carroll CB. In Patients With Melanoma Brain Metastases, Is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic. Neurologist. 2022 Sep 1; 27 (5):290-297 Epub 2022 Sept 01
    View PubMed
  15. Shah SS, Morris P, Buciuc M, Tajfirouz D, Wingerchuk DM, Weinshenker BG, Eggenberger ER, Di Nome M, Pittock SJ, Flanagan EP, Bhatti MT, Chen JJ. Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD. Neurology. 2022 Aug 23; 99 (8):e851-e857 Epub 2022 June 13
    View PubMed
  16. Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2022 Aug 18; 387 (7):631-639
    View PubMed
  17. Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Armstrong R, Wingerchuk DM, PREVENT Study Group. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Mult Scler. 2022 Mar; 28 (3):480-486 Epub 2021 Sept 09
    View PubMed
  18. Wingerchuk DM, Zhang I, Kielhorn A, Royston M, Levy M, Fujihara K, Nakashima I, Tanvir I, Paul F, Pittock SJ. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. Neurol Ther. 2022 Mar; 11 (1):123-135 Epub 2021 Nov 13
    View PubMed
  19. Callister MN, Stonnington CB, Cuc A, Alcott SB, Driver-Dunckley ED, Mehta SH, Hasan S, Marks LA, Wingerchuk DM, O'Carroll CB. In Patients With Functional Movement Disorders, Is Specialized Physical Therapy Effective in Improving Motor Symptoms?: A Critically Appraised Topic. Neurologist. 2022 Jan 20; 27 (2):82-88
    View PubMed
  20. Marignier R, Pittock SJ, Paul F, Kim HJ, Bennett JL, Weinshenker BG, Wingerchuk DM, Green AJ, Fujihara K, Cutter G, Aktas O, Hartung HP, Drappa J, Ratchford JN, She D, Smith M, Rees W, Cimbora D, Katz E, Cree BAC, N-MOmentum study investigators. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2022 Jan; 57:103356 Epub 2021 Nov 01
    View PubMed
  21. Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Mult Scler. 2021 Nov; 27 (13):2052-2061 Epub 2021 Feb 04
    View PubMed
  22. Redenbaugh V, Montalvo M, Sechi E, Buciuc M, Fryer JP, McKeon A, Lennon VA, Mills JR, Weinshenker BG, Wingerchuk DM, Chen JJ, Tariq Bhatti M, Lopez Chiriboga AS, Pittock SJ, Flanagan EP. Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. Mult Scler J Exp Transl Clin. 2021 Oct; 7 (4):20552173211052656 Epub 2021 Nov 26
    View PubMed
  23. Zhao-Fleming HH, Valencia Sanchez C, Sechi E, Inbarasu J, Wijdicks EF, Pittock SJ, Chen JJ, Wingerchuk DM, Weinshenker BG, Lopez-Chiriboga S, Dubey D, Tillema JM, Toledano M, Yadav H, Flanagan EP. CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. Neurology. 2021 Sep 28; 97 (13):e1351-e1358 Epub 2021 Aug 13
    View PubMed
  24. Gritsch D, Mrugala MM, Marks LA, Mangipudi K, Neal M, Wingerchuk DM, O'Carroll CB. Is Autologous Stem Cell Transplantation a Safe and Effective Alternative to Whole Brain Radiation as Consolidation Therapy in Patients With Primary Central Nervous System Lymphoma?: A Critically Appraised Topic. Neurologist. 2021 Jul 6; 26 (4):137-142 Epub 2021 July 06
    View PubMed
  25. Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ, PREVENT Study Group. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol. 2021 Jun; 89 (6):1088-1098 Epub 2021 Feb 27
    View PubMed
  26. Knox MG, Demaerschalk BM, Alcott SB, Marks LA, Wingerchuk DM, O'Carroll CB. Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic. Neurologist. 2021 May 5; 26 (3):112-115 Epub 2021 May 05
    View PubMed
  27. Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC, N-MOmentum Study Investigators. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2021 May; 8 (3) Epub 2021 Mar 26
    View PubMed
  28. Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K, PREVENT Study Group. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Mult Scler Relat Disord. 2021 May; 50:102849 Epub 2021 Feb 20
    View PubMed
  29. Howard LW, Demaerschalk BM, Chong BW, Bendok BR, Gritsch D, Marks LA, Wingerchuk DM, O'Carroll CB. Does General Anesthesia Compared With Conscious Sedation Result in Better Outcomes in Acute Stroke Patients Undergoing Endovascular Therapy? Neurologist. 2021 Mar 4; 26 (2):47-51 Epub 2021 Mar 04
    View PubMed
  30. Gritsch D, Mbonde AA, Harahsheh EY, Chong BW, Wingerchuk DM. Reversible Cerebral Vasculopathy, Transverse Myelitis, and Active Systemic Lupus Erythematosus in an Aquaporin-4 Antibody-Positive Patient. Neurol Neuroimmunol Neuroinflamm. 2021 Mar; 8 (2) Epub 2021 Jan 19
    View PubMed
  31. Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord. 2021 Feb; 48:102696 Epub 2020 Dec 16
    View PubMed
  32. Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S, PREVENT Study Group. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord. 2021 Jan; 47:102641 Epub 2020 Nov 26
    View PubMed
  33. Sechi E, Mariotto S, McKeon A, Krecke KN, Pittock SJ, Ferrari S, Monaco S, Flanagan EP, Zanzoni S, Rabinstein AA, Wingerchuk DM, Nasr DM, Zalewski NL. Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. Stroke. 2021 Jan; 52 (2):645-654 Epub 2021 Jan 11
    View PubMed
  34. Whittam DH, Karthikeayan V, Gibbons E, Kneen R, Chandratre S, Ciccarelli O, Hacohen Y, de Seze J, Deiva K, Hintzen RQ, Wildemann B, Jarius S, Kleiter I, Rostasy K, Huppke P, Hemmer B, Paul F, Aktas O, Probstel AK, Arrambide G, Tintore M, Amato MP, Nosadini M, Mancardi MM, Capobianco M, Illes Z, Siva A, Altintas A, Akman-Demir G, Pandit L, Apiwattankul M, Hor JY, Viswanathan S, Qiu W, Kim HJ, Nakashima I, Fujihara K, Ramanathan S, Dale RC, Boggild M, Broadley S, Lana-Peixoto MA, Sato DK, Tenembaum S, Cabre P, Wingerchuk DM, Weinshenker BG, Greenberg B, Matiello M, Klawiter EC, Bennett JL, Wallach AI, Kister I, Banwell BL, Traboulsee A, Pohl D, Palace J, Leite MI, Levy M, Marignier R, Solomon T, Lim M, Huda S, Jacob A. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020 Dec; 267 (12):3565-3577 Epub 2020 July 04
    View PubMed
  35. Kunchok A, Chen JJ, Saadeh RS, Wingerchuk DM, Weinshenker BG, Flanagan EP, Pittock SJ. Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. JAMA Neurol. 2020 Dec 1; 77 (12):1572-1575
    View PubMed
  36. Valencia-Sanchez C, Wingerchuk DM, Dhamija R. Teaching NeuroImages: Spinal xanthomatosis: A misdiagnosed, treatable cause of progressive myelopathy. Neurology. 2020 Sep 15; 95 (11):e1615-e1616 Epub 2020 July 07
    View PubMed
  37. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020 Jul 14; 95 (2):e111-e120 Epub 2020 June 17
    View PubMed
  38. Valencia-Sanchez C, Wingerchuk DM. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. Mult Scler Relat Disord. 2020 Jul; 42:102182 Epub 2020 May 08
    View PubMed
  39. Blech B, Starling AJ, Marks LA, Wingerchuk DM, O'Carroll CB. Is Noninvasive Vagus Nerve Stimulation a Safe and Effective Alternative to Medication for Acute Migraine Control? Neurologist. 2020 Jul; 25 (4):97-100
    View PubMed
  40. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, Jacob A, Marignier R, Weinshenker BG, Paul F, Pittock SJ, Palace J, Wingerchuk DM, Behne JM, Yeaman MR, Fujihara K. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020; 11:501 Epub 2020 June 26
    View PubMed
  41. Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E, N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019 Oct 12; 394 (10206):1352-1363 Epub 2019 Sept 05
    View PubMed
  42. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 Aug 15; 381 (7):614-625 Epub 2019 May 03
    View PubMed
  43. Wingerchuk DM. Disease-modifying therapies should be stopped in NMOSD patients in remission - Commentary. Mult Scler. 2019 Aug; 25 (9):1220-1222 Epub 2019 Mar 22
    View PubMed
  44. Valencia-Sanchez C, Goodman BP, Carter JL, Wingerchuk DM. The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations. Mult Scler. 2019 May; 25 (6):758-765 Epub 2019 Jan 18
    View PubMed
  45. Sechi E, Morris PP, McKeon A, Pittock SJ, Hinson SR, Weinshenker BG, Aksamit AJ, Krecke KN, Kaufmann TJ, Jolliffe EA, Zalewski NL, Zekeridou A, Wingerchuk DM, Jitprapaikulsan J, Flanagan EP. Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J Neurol Neurosurg Psychiatry 2019 Apr; 90 (4):488-490 Epub 2018 July 21
    View PubMed
  46. Ornelas AS, Porter AB, Sharma A, Knox MG, Marks LA, Wingerchuk DM, O'Carroll CB. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma? Neurologist. 2019 Mar; 24 (2):71-73
    View PubMed
  47. Arca KN, Demaerschalk BM, Almader-Douglas D, Wingerchuk DM, O'Carroll CB. Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke? Neurologist. 2019 Jan; 24 (1):40-43
    View PubMed
  48. Blech B, Chong BW, Sands KA, Wingerchuk DM, Jackson WT, Marks LA, O'Carroll CB. Are Postprocedural Blood Pressure Goals Associated With Clinical Outcome After Mechanical Thrombectomy for Acute Ischemic Stroke? Neurologist. 2019 Jan; 24 (1):44-47
    View PubMed
  49. Chen JJ, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga AS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. Am J Ophthalmol. 2018 Nov; 195:8-15 Epub 2018 July 26
    View PubMed
  50. López-Chiriboga AS, Majed M, Fryer J, Dubey D, McKeon A, Flanagan EP, Jitprapaikulsan J, Kothapalli N, Tillema JM, Chen J, Weinshenker B, Wingerchuk D, Sagen J, Gadoth A, Lennon VA, Keegan BM, Lucchinetti C, Pittock SJ. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurol. 2018 Nov 01; 75(11):1355-1363.
    View PubMed
  51. Mealy MA, Kim SH, Schmidt F, Lopez R, Jimenez Arango JA, Paul F, Wingerchuk DM, Greenberg BM, Kim HJ, Levy M. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler. 2018 Nov; 24 (13):1737-1742 Epub 2017 Aug 31
    View PubMed
  52. McCreary M, Mealy MA, Wingerchuk DM, Levy M, DeSena A, Greenberg BM. Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts. Mult Scler J Exp Transl Clin. 2018 Oct-Dec; 4 (4):2055217318815925 Epub 2018 Dec 06
    View PubMed
  53. Valencia-Sanchez C, Fortuin FD, Sweeney JP, Ingall TJ, Marks LA, Wingerchuk DM, O'Carroll CB. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic. Neurologist. 2018 Sep; 23 (5):175-180
    View PubMed
  54. Corboy JR, Weinshenker BG, Wingerchuk DM. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. Neurology. 2018 Jun 12; 90 (24):1106-1112 Epub 2018 Apr 23
    View PubMed
  55. Valencia-Sanchez C, Crepeau AZ, Hoerth MT, Butler KA, Almader-Douglas D, Wingerchuk DM, O'Carroll CB. Is Adjunctive Progesterone Effective in Reducing Seizure Frequency in Patients With Intractable Catamenial Epilepsy? A Critically Appraised Topic. Neurologist. 2018 May; 23 (3):108-112
    View PubMed
  56. Wingerchuk DM. Immune-Mediated Myelopathies. Continuum (Minneap Minn). 2018 Apr; 24 (2, Spinal Cord Disorders):497-522
    View PubMed
  57. Chiang CC, Dumitrascu OM, Wingerchuk DM, O'Carroll CB. Acute Basilar Artery Occlusion: Does Recanalization Improve Clinical Outcome? A Critically Appraised Topic. Neurologist. 2018 Mar; 23(2):71-74.
    View PubMed
  58. Christiansen ME, Van Woerkom RC, Demaerschalk BM, Wingerchuk DM, O'Carroll CB. What is Clinical Efficacy of Transesophageal Echocardiography in Patients With Cryptogenic Stroke?: A Critically Appraised Topic. Neurologist. 2018 Jan; 23 (1):30-33
    View PubMed
  59. Parks NE, Flanagan EP, Lucchinetti CF, Wingerchuk DM. NEDA treatment target? No evident disease activity as an actionable outcome in practice. J Neurol Sci. 2017 Dec 15; 383:31-34 Epub 2017 Oct 13
    View PubMed
  60. Klawiter EC, Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy MA, Sorum J, Mutch K, Tobyne SM, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Paul F, Cross AH, Jacobs A, Chitnis T, Weinshenker B. High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology. 2017 Nov 28; 89 (22):2238-2244 Epub 2017 Nov 01
    View PubMed
  61. Dumitrascu OM, Shen JF, Kurli M, Aguilar MI, Marks LA, Demaerschalk BM, Wingerchuk DM, O'Carroll CB. Is Intravenous Thrombolysis Safe and Effective in Central Retinal Artery Occlusion? A Critically Appraised Topic. Neurologist. 2017 Jul; 22 (4):153-156
    View PubMed
  62. Dubey D, Singh J, Britton JW, Pittock SJ, Flanagan EP, Lennon VA, Tillema JM, Wirrell E, Shin C, So E, Cascino GD, Wingerchuk DM, Hoerth MT, Shih JJ, Nickels KC, McKeon A. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia. 2017 Jul; 58 (7):1181-1189 Epub 2017 May 26
    View PubMed
  63. Bove R, Elsone L, Alvarez E, Borisow N, Cortez MM, Mateen FJ, Mealy MA, Mutch K, Tobyne S, Ruprecht K, Buckle G, Levy M, Wingerchuk DM, Paul F, Cross AH, Weinshenker B, Jacob A, Klawiter EC, Chitnis T. Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm. 2017 May; 4 (3):e339 Epub 2017 Mar 24
    View PubMed
  64. Weinshenker BG, Wingerchuk DM. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017 Apr; 92 (4):663-679
    View PubMed
  65. Zalewski NL, Morris PP, Weinshenker BG, Lucchinetti CF, Guo Y, Pittock SJ, Krecke KN, Kaufmann TJ, Wingerchuk DM, Kumar N, Flanagan EP. Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2017 Mar; 88 (3):218-225 Epub 2016 Dec 02
    View PubMed
  66. Sathiamoorthi S, Wingerchuk DM. Transient smartphone blindness: Relevance to misdiagnosis in neurologic practice. Neurology. 2017 Feb 21; 88 (8):809-810 Epub 2017 Jan 18
    View PubMed
  67. Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology. 2016 Sep 27; 87 (13):1393-9 Epub 2016 Aug 31
    View PubMed
  68. Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016 Aug 22; 354:i3518
    View PubMed
  69. Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler. 2016 Jun; 22 (7):862-72 Epub 2015 Dec 14
    View PubMed
  70. Flanagan EP, Cabre P, Weinshenker BG, Sauver JS, St Sauver J, Jacobson DJ, Majed M, Lennon VA, Lucchinetti CF, McKeon A, Matiello M, Kale N, Wingerchuk DM, Mandrekar J, Sagen JA, Fryer JP, Robinson AB, Pittock SJ. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. 2016 May; 79 (5):775-783 Epub 2016 Apr 04
    View PubMed
  71. Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, Itoh N, Bardens J, Bernard JT, Corboy JR, Cross AH, Dhib-Jalbut S, Ford CC, Frohman EM, Giesser B, Jacobs D, Kasper LH, Lynch S, Parry G, Racke MK, Reder AT, Rose J, Wingerchuk DM, MacKenzie-Graham AJ, Arnold DL, Tseng CH, Elashoff R. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Jan; 15 (1):35-46 Epub 2015 Nov 29
    View PubMed
  72. Jurynczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Seze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol. 2016 Jan; 263 (1):140-9 Epub 2015 Nov 03
    View PubMed
  73. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14; 85 (2):177-89 Epub 2015 June 19
    View PubMed
  74. Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stuve O, Aktas O, Smith TJ, Jacob A, O'Connor K, Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2015 Jul; 72 (7):815-22
    View PubMed
  75. Cortez MM, Nagi Reddy SK, Goodman B, Carter JL, Wingerchuk DM. Autonomic symptom burden is associated with MS-related fatigue and quality of life. Mult Scler Relat Disord. 2015 May; 4: (3)258-63.
    View PubMed
  76. Dhawan PS, Goodman BP, Harper CM, Bosch PE, Hoffman-Snyder CR, Wellik KE, Wingerchuk DM, Demaerschalk BM. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic. Neurologist. 2015 May; 19 (5):145-8
    View PubMed
  77. Weinshenker BG, Barron G, Behne JM, Bennett JL, Chin PS, Cree BA, de Seze J, Flor A, Fujihara K, Greenberg B, Higashi S, Holt W, Khan O, Knappertz V, Levy M, Melia AT, Palace J, Smith TJ, Sormani MP, Van Herle K, VanMeter S, Villoslada P, Walton MK, Wasiewski W, Wingerchuk DM, Yeaman MR, Guthy-Jackson Charitable Foundation International Clinical Consortium. Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology. 2015 Apr 28; 84 (17):1805-15 Epub 2015 Apr 03
    View PubMed
  78. Schlosser Covell GE, Hoffman-Snyder CR, Wellik KE, Woodruff BK, Geda YE, Caselli RJ, Demaerschalk BM, Wingerchuk DM. Physical activity level and future risk of mild cognitive impairment or dementia: a critically appraised topic. Neurologist. 2015 Feb; 19: (3)89-91.
    View PubMed
  79. Popescu BF, Guo Y, Jentoft ME, Parisi JE, Lennon VA, Pittock SJ, Weinshenker BG, Wingerchuk DM, Giannini C, Metz I, Bruck W, Shuster EA, Carter J, Boyd CD, Clardy SL, Cohen BA, Lucchinetti CF. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology. 2015 Jan 13; 84 (2):148-58 Epub 2014 Dec 10
    View PubMed
  80. Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, Wingerchuk DM, Shuster EA, Jiao Y, Horta ES, Pittock SJ. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2015 Jan; 72 (1):81-7
    View PubMed
  81. Spritzer SD, Kinney CL, Condie J, Wellik KE, Hoffman-Snyder CR, Wingerchuk DM, Demaerschalk BM. Amantadine for patients with severe traumatic brain injury: a critically appraised topic. Neurologist. 2015 Jan; 19 (2):61-4
    View PubMed
  82. Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol. 2014 Oct; 5 (3):290-303 Epub 2014 Apr 22
    View PubMed
  83. Fryer JP, Lennon VA, Pittock SJ, Jenkins SM, Fallier-Becker P, Clardy SL, Horta E, Jedynak EA, Lucchinetti CF, Shuster EA, Weinshenker BG, Wingerchuk DM, McKeon A. AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm. 2014 Jun; 1 (1):e11 Epub 2014 May 22
    View PubMed
  84. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol. 2014 Mar; 71 (3):324-30
    View PubMed
  85. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb; 89 (2):225-40
    View PubMed
  86. Thaera GM, Wingerchuk DM, Carter JL. Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis. Mult Scler Relat Disord. 2014 Jan; 3(1):107-9. Epub 2013 Jun 15.
    View PubMed
  87. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica (Devic's syndrome). Handb Clin Neurol. 2014; 122:581-99.
    View PubMed
  88. Jiao Y, Fryer JP, Lennon VA, McKeon A, Jenkins SM, Smith CY, Quek AM, Weinshenker BG, Wingerchuk DM, Shuster EA, Lucchinetti CF, Pittock SJ. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol. 2014 Jan; 71 (1):48-54
    View PubMed
  89. Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AM, Smith CY, McKeon A, Costanzi C, Iorio R, Weinshenker BG, Wingerchuk DM, Shuster EA, Lucchinetti CF, Pittock SJ. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013 Oct 1; 81 (14):1197-204 Epub 2013 Aug 30
    View PubMed
  90. Wingerchuk DM, Weinshenker BG. Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica. Continuum (Minneap Minn). 2013 Aug; 19(4 Multiple Sclerosis):944-67.
    View PubMed
  91. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013 Jun; 12(6):554-62. Epub 2013 Apr 26.
    View PubMed
  92. Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol. 2013 Jan; 33 Suppl 1:S33-7 Epub 2012 Sept 14
    View PubMed
  93. Bravo TP, Hoffman-Snyder CR, Wellik KE, Martin KA, Hoerth MT, Demaerschalk BM, Wingerchuk DM. The effect of selective serotonin reuptake inhibitors on the frequency of psychogenic nonepileptic seizures: a critically appraised topic. Neurologist. 2013 Jan; 19 (1):30-3
    View PubMed
  94. Schlosser Covell GE, Dhawan PS, Lee Iannotti JK, Hoffman-Snyder CR, Wellik KE, Caselli RJ, Woodruff BK, Wingerchuk DM, Demaerschalk BM. Disrupted daytime activity and altered sleep-wake patterns may predict transition to mild cognitive impairment or dementia: a critically appraised topic. Neurologist. 2012 Nov; 18: (6)426-9.
    View PubMed
  95. Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, Marignier R, Nakashima I, Palace J, de Seze J, Stuve O, Tenembaum SN, Traboulsee A, Waubant E, Weinshenker BG, Wingerchuk DM, GJCF-CC&BR. Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord. 2012 Oct; 1 (4):180-187
    View PubMed
  96. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012 Sep; 69(9):1176-80.
    View PubMed
  97. Spritzer SD, Hoerth MT, Zimmerman RS, Shmookler A, Hoffman-Snyder CR, Wellik KE, Demaerschalk BM, Wingerchuk DM. Determination of hemispheric language dominance in the surgical epilepsy patient: diagnostic properties of functional magnetic resonance imaging. Neurologist. 2012 Sep; 18 (5):329-31
    View PubMed
  98. Quek AM, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, Costanzi C, Weinshenker BG, Wingerchuk DM, Lucchinetti CF, Shuster EA, Pittock SJ. Effects of age and sex on aquaporin-4 autoimmunity. Arch Neurol. 2012 Aug; 69 (8):1039-43
    View PubMed
  99. Lee-Iannotti JK, Capampangan DJ, Hoffman-Snyder C, Wellik KE, Patel B, Tondato F, Wingerchuk DM, Demaerschalk BM. New-onset atrial fibrillation in severe sepsis and risk of stroke and death: a critically appraised topic. Neurologist. 2012 Jul; 18(4):239-43.
    View PubMed
  100. Morrow MJ, Wingerchuk D. Neuromyelitis optica. J Neuroophthalmol. 2012 Jun; 32(2):154-66.
    View PubMed
  101. Kramer C, Freeman WD, Larson JS, Hoffman-Snyder C, Wellik KE, Hoffman-Snyder C, Demaerschalk BM, Wingerchuk DM. Therapeutic hypothermia for severe traumatic brain injury: a critically appraised topic. Neurologist. 2012 May; 18 (3):173-7
    View PubMed
  102. Mealy MA, Newsome S, Greenberg BM, Wingerchuk D, Calabresi P, Levy M. Low serum vitamin D levels and recurrent inflammatory spinal cord disease. Arch Neurol. 2012 Mar; 69(3):352-6. Epub 2011 Nov 14.
    View PubMed
  103. Adcock AK, Lee-Iannotti JK, Aguilar MI, Hoffman-Snyder CR, Wingerchuk DM, Wellik KE, Demaerschalk BM. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. Neurologist. 2012 Mar; 18(2):102-7.
    View PubMed
  104. Wingerchuk DM. Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord. 2012 Jan; 5(1):13-22.
    View PubMed
  105. O'Carroll CB, Woodruff BK, Locke DE, Hoffman-Snyder CR, Wellik KE, Thaera GM, Demaerschalk BM, Wingerchuk DM. Is donepezil effective for multiple sclerosis-related cognitive dysfunction? A critically appraised topic. Neurologist. 2012 Jan; 18 (1):51-4
    View PubMed
  106. Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012 Jan; 18 (1):5-10 Epub 2011 Dec 06
    View PubMed
  107. Kramer C, Aguilar MI, Hoffman-Snyder C, Wellik KE, Wingerchuk DM, Demaerschalk BM. Safety and efficacy of ultrasound-enhanced thrombolysis in the treatment of acute middle cerebral artery infarction: a critically appraised topic. Neurologist. 2011 Nov; 17: (6)346-51.
    View PubMed
  108. Starling AJ, Hoffman-Snyder C, Halker RB, Wellik KE, Vargas BB, Dodick DW, Demaerschalk BM, Wingerchuk DM. Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic. Neurologist. 2011 Sep; 17(5):297-9.
    View PubMed
  109. O'Carroll CB, Capampangan DJ, Aguilar MI, Bravo TP, Hoffman-Snyder CR, Wingerchuk DM, Wellik KE, Demaerschalk BM. What is the effect of low-molecular weight heparin for venous thromboembolism prophylaxis compared with mechanical methods, on the occurrence of hemorrhagic and venous thromboembolic complications in patients with intracerebral hemorrhage? A critically appraised topic. Neurologist. 2011 Jul; 17(4):232-5.
    View PubMed
  110. Ziemba KS, Wellik KE, Hoffman-Snyder C, Noe KH, Demaerschalk BM, Wingerchuk DM. Timing of antiepileptic drug withdrawal in adult epilepsy patients after neocortical surgical resection: a critically appraised topic. Neurologist. 2011 May; 17(3):176-8.
    View PubMed
  111. Riordan KC, Hoffman Snyder CR, Wellik KE, Caselli RJ, Wingerchuk DM, Demaerschalk BM. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic. Neurologist. 2011 Mar; 17 (2):121-3
    View PubMed
  112. Wingerchuk DM. Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mt Sinai J Med. 2011 Mar-Apr; 78 (2):221-30
    View PubMed
  113. Starling AJ, Wellik KE, Hoffman Snyder CR, Aguilar MI, Demaerschalk BM, Zimmerman RS, Wingerchuk DM. Surgical decompression improves mortality and morbidity after large territory acute cerebral infarction: a critically appraised topic. Neurologist. 2011 Jan; 17(1):63-6.
    View PubMed
  114. Riordan KC, Wingerchuk DM, Wellik KE, Zimmerman RS, Sirven JI, Noe KH, Patel BM, Demaerschalk BM. Anticonvulsant drug therapy after aneurysmal subarachnoid hemorrhage: a critically appraised topic. Neurologist. 2010 Nov; 16(6):397-9.
    View PubMed
  115. Wingerchuk DM. Neuromyelitis optica spectrum disorders. Continuum. 2010 Oct; 16(5):105-21.
  116. Ziemba KS, O'Carroll CB, Drazkowski JF, Wingerchuk DM, Hoffman-Snyder C, Wellik KE, Demaerschalk BM. Do antiepileptic drugs increase the risk of suicidality in adult patients with epilepsy?: a critically appraised topic. Neurologist. 2010 Sep; 16(5):325-8.
    View PubMed
  117. Frohman EM, Wingerchuk DM. Clinical practice. Transverse myelitis. N Engl J Med. 2010 Aug 5; 363(6):564-72.
    View PubMed
  118. Capampangan DJ, Wellik KE, Parish JM, Aguilar MI, Snyder CR, Wingerchuk D, Demaerschalk BM. Is obstructive sleep apnea an independent risk factor for stroke? A critically appraised topic. Neurologist. 2010 Jul; 16(4):269-73.
    View PubMed
  119. Gilmore CP, Cottrell DA, Scolding NJ, Wingerchuk DM, Weinshenker BG, Boggild M. A window of opportunity for no treatment in early multiple sclerosis? Mult Scler. 2010 Jun; 16(6):756-9. Epub 2010 Apr 28.
    View PubMed
  120. Zarkou S, Carter JL, Wellik KE, Demaerschalk BM, Wingerchuk DM. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic. Neurologist. 2010 May; 16(3):212-4.
    View PubMed
  121. Thaera GM, Wellik KE, Barrs DM, Dunckley ED, Wingerchuk DM, Demaerschalk BM. Are corticosteroid and antiviral treatments effective for bell palsy? A critically appraised topic. Neurologist. 2010 Mar; 16(2):138-40.
    View PubMed
  122. Hlubocky A, Wellik K, Ross MA, Smith BE, Hoffman-Snyder C, Demaerschalk BM, Wingerchuk DM. Skin biopsy for diagnosis of small fiber neuropathy: a critically appraised topic. Neurologist. 2010 Jan; 16(1):61-3.
    View PubMed
  123. Wingerchuk DM. Multiple sclerosis. Medical Knowledge Self-Assessment Program (MKSAP) 15. American College of Physicians. 2009 Dec.
  124. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009 Nov 15; 286 (1-2):18-23 Epub 2009 Sept 08
    View PubMed
  125. Thaera GM, Wellik KE, Carter JL, Demaerschalk BM, Wingerchuk DM. Do cannabinoids reduce multiple sclerosis-related spasticity? Neurologist. 2009 Nov; 15(6):369-71.
    View PubMed
  126. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, Lucchinetti CF, Weinshenker BG, Wingerchuk DM, Shuster EA, Pittock SJ. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009 Sep; 66 (9):1134-8
    View PubMed
  127. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009 Sep; 66 (9):1128-33
    View PubMed
  128. Zarkou S, Aguilar MI, Patel NP, Wellik KE, Wingerchuk DM, Demaerschalk BM. The role of corticosteroids in the management of chronic subdural hematomas: a critically appraised topic. Neurologist. 2009 Sep; 15(5):299-302.
    View PubMed
  129. Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN, Wingerchuk DM. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. Neurologist. 2009 Jul; 15(4):234-7.
    View PubMed
  130. Capampangan DJ, Wellik KE, Bobrow BJ, Aguilar MI, Ingall TJ, Kiernan TE, Wingerchuk DM, Demaerschalk BM. Telemedicine versus telephone for remote emergency stroke consultations: a critically appraised topic. Neurologist. 2009 May; 15 (3):163-6
    View PubMed
  131. Khoury J, Wellik KE, Demaerschalk BM, Wingerchuk DM. Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis. Neurologist. 2009 Mar; 15 (2):108-11
    View PubMed
  132. Arendt K, Demaerschalk BM, Wingerchuk DM, Camann W. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan; 15(1):17-20.
    View PubMed
  133. McKeon A, Lennon VA, Jacob A, Matiello M, Lucchinetti CF, Kale N, Chan KH, Weinshenker BG, Apiwattinakul M, Wingerchuk DM, Pittock SJ. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve. 2009 Jan; 39(1):87-90.
    View PubMed
  134. Almaraz AC, Bobrow BJ, Wingerchuk DM, Wellik KE, Demaerschalk BM. Serum neuron specific enolase to predict neurological outcome after cardiopulmonary resuscitation: a critically appraised topic. Neurologist. 2009 Jan; 15(1):44-8.
    View PubMed
  135. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008 Nov; 65 (11):1443-8 Epub 2008 Sept 08
    View PubMed
  136. Capampangan DJ, Wellik KE, Aguilar MI, Demaerschalk BM, Wingerchuk DM. Does prophylactic postoperative hypervolemic therapy prevent cerebral vasospasm and improve clinical outcome after aneurysmal subarachnoid hemorrhage? Neurologist. 2008 Nov; 14(6):395-8.
    View PubMed
  137. Vargas BB, Dodick DW, Wingerchuk DM, Demaerschalk BM. Migraine with and without aura and risk for cardiovascular disease. Curr Atheroscler Rep. 2008 Oct; 10 (5):427-33
    View PubMed
  138. Khoury JA, Hoxworth JM, Mazlumzadeh M, Wellik KE, Wingerchuk DM, Demaerschalk BM. The clinical utility of high resolution magnetic resonance imaging in the diagnosis of giant cell arteritis: a critically appraised topic. Neurologist. 2008 Sep; 14(5):330-5.
    View PubMed
  139. Hoerth MT, Wellik KE, Demaerschalk BM, Drazkowski JF, Noe KH, Sirven JI, Wingerchuk DM. Clinical predictors of psychogenic nonepileptic seizures: a critically appraised topic. Neurologist. 2008 Jul; 14(4):266-70.
    View PubMed
  140. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008 Jun 3; 70(23):2197-200. Epub 2008 Apr 23.
    View PubMed
  141. Wingerchuk DM. Infectious and inflammatory myelopathies. Continuum. 2008 Jun; 14(3):36-57.
  142. Wingerchuk DM, Dyck PJ, Mertz LE. Hemi-meningitis: A focal sign heralding a multisystem necrotizing vasculitis. Neurology. 2008 May 20; 70(21):2014.
    View PubMed
  143. Halker RB, Barrs DM, Wellik KE, Wingerchuk DM, Demaerschalk BM. Establishing a diagnosis of benign paroxysmal positional vertigo through the dix-hallpike and side-lying maneuvers: a critically appraised topic. Neurologist. 2008 May; 14 (3):201-4
    View PubMed
  144. Schrader SL, Wellik KE, Demaerschalk BM, Caselli RJ, Woodruff BK, Wingerchuk DM. Adjunctive haloperidol prophylaxis reduces postoperative delirium severity and duration in at-risk elderly patients. Neurologist. 2008 Mar; 14(2):134-7.
    View PubMed
  145. Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol. 2008 Feb; 28(1):56-68.
    View PubMed
  146. Goodman BP, Schroder SL, Demaerschalk BM, Wingerchuk DM. A new system to acquire and restore document shape and content. PROCAMS. 2008 - ACM/IEEE 5th International Workshop on Projector Camera Systems. 2008; 12.
  147. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol. 2008 Jan; 10 (1):55-66
    View PubMed
  148. Miley ML, Wellik KE, Wingerchuk DM, Demaerschalk BM. Does cervical manipulative therapy cause vertebral artery dissection and stroke? Neurologist. 2008 Jan; 14(1):66-73.
    View PubMed
  149. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zephir H, Moder K, Weinshenker BG. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008 Jan; 65 (1):78-83
    View PubMed
  150. Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol. 2008; 318:343-56
    View PubMed
  151. McKeon A, Lennon VA, Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti CF, Pittock SJ. Neuromyelitis optica and coexisting neurological autoimmunity [in press]. Arch Neurol. 2008.
  152. Wingerchuk DM. Neuromyelitis optica: recent advances and characteristics of visual dysfunction [in press]. Curr Med Lit Ophthalmol. 2008.
  153. Hoerth MT, Wellik KE, Noe KH, Demaerschalk BM, Wingerchuk DM. Can clinical observations accurately differentiate nonepileptic from epileptic seizures [in press]? Neurologist. 2008.
  154. Khoury JA, Wellik KE, Hoxworth JM, Wingerchuk DM, Demaerschalk BM. MRI for diagnosis of giant cell arteritis [in press]. Neurologist. 2008.
  155. McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM. Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders? Neurologist. 2007 Nov; 13(6):382-5.
    View PubMed
  156. Demaerschalk BM, Wingerchuk DM. The MERITs of evidence-based clinical practice in neurology. Semin Neurol. 2007 Sep; 27(4):303-11.
    View PubMed
  157. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 Sep; 6 (9):805-15
    View PubMed
  158. Halker RB, Demaerschalk BM, Wellik KE, Wingerchuk DM, Rubin DI, Crum BA, Dodick DW. Caffeine for the prevention and treatment of postdural puncture headache: debunking the myth. Neurologist. 2007 Sep; 13(5):323-7.
    View PubMed
  159. Wingerchuk DM, Spencer B, Dodick DW, Demaerschalk BM. Migraine with aura is a risk factor for cardiovascular and cerebrovascular disease: a critically appraised topic. Neurologist. 2007 Jul; 13(4):231-3.
    View PubMed
  160. Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: changing concepts. J Neuroimmunol. 2007 Jul; 187(1-2):126-38. Epub 2007 May 21.
    View PubMed
  161. Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Opin Neurol. 2007 Jun; 20 (3):255-60
    View PubMed
  162. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol. 2007 Jun; 20(3):343-50.
    View PubMed
  163. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007 May; 130 (Pt 5):1194-205 Epub 2007 Feb 04
    View PubMed
  164. Tang J, Wingerchuk DM, Crum BA, Rubin DI, Demaerschalk BM. Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy. Neurologist. 2007 May; 13(3):164-7.
    View PubMed
  165. Hickey MG, Demaerschalk BM, Caselli RJ, Parish JM, Wingerchuk DM. "Idiopathic" rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseases. Neurologist. 2007 Mar; 13(2):98-101.
    View PubMed
  166. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007 Feb 20; 68 (8):603-5
    View PubMed
  167. Wingerchuk DM. Neuromyelitis optica: new findings on pathogenesis. Int Rev Neurobiol. 2007; 79:665-88.
    View PubMed
  168. Demaerschalk BM, Wingerchuk DM. Treatment of vascular dementia and vascular cognitive impairment. Neurologist. 2007 Jan; 13(1):37-41.
    View PubMed
  169. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist. 2007 Jan; 13(1):2-11.
    View PubMed
  170. Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF. Second-generation antiepileptic drugs' impact on balance: a meta-analysis. Mayo Clin Proc. 2007 Jan; 82 (1):40-7
    View PubMed
  171. Porter A, Lyons MK, Wingerchuk DM, Bosch EP. Spinal cord astrocytoma presenting as "idiopathic" intracranial hypertension. Clin Neurol Neurosurg. 2006 Dec; 108(8):787-9. Epub 2005 Nov 18.
    View PubMed
  172. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006 Jul; 63 (7):964-8
    View PubMed
  173. Wingerchuk DM, Rodriguez M. Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin. Arch Neurol. 2006 Jul; 63 (7):1005-8
    View PubMed
  174. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new insights. Curr Opin Neurol. 2006 Jun; 19 (3):248-54
    View PubMed
  175. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 May 23; 66 (10):1485-9
    View PubMed
  176. Wingerchuk DM. Neuromyelitis optica. Int MS J. 2006 May; 13: (2)42-50.
    View PubMed
  177. Wingerchuk DM. The clinical course of acute disseminated encephalomyelitis. Neurol Res. 2006 Apr; 28(3):341-7.
    View PubMed
  178. Wingerchuk DM. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res. 2006 Apr; 28(3):348-53.
    View PubMed
  179. Wingerchuk DM. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management. Expert Rev Neurother. 2006 Mar; 6(3):333-46.
    View PubMed
  180. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006 Mar; 129(Pt 3):584-94. Epub 2006 Jan 09.
    View PubMed
  181. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, Lennon VA. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006 Mar; 59 (3):566-9
    View PubMed
  182. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006 Mar; 63 (3):390-6
    View PubMed
  183. Guimaraes J, Wingerchuk D, Sa MJ. Devic's disease with serological confirmation. [Portuguese]. Sinapse. 2006; 6(1):69-74.
  184. Weinshenker BG, Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA. NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers. 2006; 22 (4):197-206
    View PubMed
  185. Wingerchuk DM. Neuromyelitis optica. Adv Neurol. 2006; 98:319-33.
    View PubMed
  186. Wingerchuk DM. Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues. Adv Neurol. 2006; 98:303-18.
    View PubMed
  187. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005 Sep; 76 (9):1294-6
    View PubMed
  188. Wingerchuk DM, Patel NP, Patel AC, Dodick DW, Nelson KD. Progressive cervical myelopathy secondary to chronic ventriculoperitoneal CSF overshunting. Neurology. 2005 Jul 12; 65(1):171-2.
  189. Wingerchuk DM. Diagnosis of Neuromyelitis Optica (Syndrome). Veterans Affairs MS Centers of Excellence website (http//www.va.gov/ms/defaultasp?action=article&ID=78). 2005 Jun 15;
  190. Wingerchuk DM, Weinshenker BG. Neuromyelitis Optica. Curr Treat Options Neurol. 2005 May; 7 (3):173-182
    View PubMed
  191. Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005 Apr 12; 64(7):1267-9.
    View PubMed
  192. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17; 364 (9451):2106-12
    View PubMed
  193. Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004 Dec; 79 (12):1489-94
    View PubMed
  194. Wingerchuk D. Cannabis for medical purposes: cultivating science, weeding out the fiction. Lancet. 2004 Jul 24-30; 364 (9431):315-6
    View PubMed
  195. Wingerchuk DM. Neuromyelitis optica: current concepts. Front Biosci. 2004 Jan 1; 9:834-40 Epub 2004 Jan 01
    View PubMed
  196. Wingerchuk DM. Is multiple sclerosis a single disease or multiple diseases? Multiple Sclerosis Quarterly Report. 2003 Winter; 22(4):9-11.
  197. Wingerchuk DM, Carter JL. Practical consultations: Multiple sclerosis. Semin Neurol. 2003 Sep; 23(3):253-64.
    View PubMed
  198. Wingerchuk DM. Postinfectious encephalomyelitis. Curr Neurol Neurosci Rep. 2003 May; 3 (3):256-64
    View PubMed
  199. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003 Mar 11; 60 (5):848-53
    View PubMed
  200. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002 Jul; 125 (Pt 7):1450-61
    View PubMed
  201. Sirven JI, Claypool DW, Sahs KL, Wingerchuk DM, Bortz JJ, Drazkowski J, Caselli R, Drazkowski J, Zanick D. Is there a neurologist on this flight? Neurology. 2002 Jun 25; 58 (12):1739-44
    View PubMed
  202. Wingerchuk DM, Noseworthy JH. Randomized controlled trials to assess therapies for multiple sclerosis. Neurology. 2002 Apr 23; 58 (8 Suppl 4):S40-8
    View PubMed
  203. Martinez-Arizala A, Barnes G, Benjamin S, Bowen J, Cutter N, Dietrich D, Dowling M, Griffin J, Irani D, Jorens P, Kaplin A, Katz J, Kerr D, Levy C, Lucchinetti CF, Lynn J, Mandler R, McDonald J, Morrison L, Pardo C, Pidcock F, Ransohoff R, Trovato M, Wegener S, Weinshenker B, Wingerchuk D, Vollmer T. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002:499-505.
  204. Jadad A, O'Brien MA, Wingerchuk D, Angle P, Biagi H, Denkers M, Tamayo C, Gauld M. Management of chronic central neuropathic pain following traumatic spinal cord injury. Evid Rep Technol Assess (Summ). 2001 Sep; (45)1-5.
    View PubMed
  205. Jadad A, O'Brien MA, Wingerchuk DM, Angle P, Biagi H, Denkers M, Tamayo C, Gauld M. Management of chronic central neuropathic pain following traumatic spinal cord injury. AHRQ Publication: Agency for Healthcare Research and Quality. 2001 Sep; 01-E063.
  206. Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA, Auger RG, Weinshenker BG, Dodick DW, Wingerchuk DM, Rodriguez M, Rodriguez M. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001 Jun 12; 56 (11):1514-22
    View PubMed
  207. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple sclerosis: current pathophysiological concepts. Lab Invest. 2001 Mar; 81 (3):263-81
    View PubMed
  208. Sirven JI, Sperling M, Wingerchuk DM. Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev. 2001; (3):CD001902
    View PubMed
  209. Wingerchuk DM, Nyquist PA, Rodriguez M, Dodick DW. Extratrigeminal short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT): new pathophysiologic entity or variation on a theme? Cephalalgia. 2000 Mar; 20 (2):127-9
    View PubMed
  210. Ebers GC, Koopman WJ, Hader W, Sadovnick AD, Kremenchutzky M, Mandalfino P, Wingerchuk DM, Baskerville J, Rice GPA. The natural history of multiple sclerosis: a geographically based study. Brain. 2000; 123:641-9.
    View PubMed
  211. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999 Sep 22; 53 (5):1107-14
    View PubMed
  212. Wingerchuk DM, Weinshenker BG. The natural history of multiple sclerosis: implications for trial design. Curr Opin Neurol. 1999 Jun; 12 (3):345-9
    View PubMed
  213. Weinshenker BG, Hebrink D, Wingerchuk DM, Klein CJ, Atkinson E, Atkinson E, O'Brien PC, McMurray CT. Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS. Neurology. 1999 Apr 22; 52 (7):1500-3
    View PubMed
  214. Wingerchuk DM, Noseworthy JH, Kimmel DW. Paraneoplastic encephalomyelitis and seminoma: importance of testicular ultrasonography. Neurology. 1998 Nov; 51 (5):1504-7
    View PubMed
  215. Wingerchuk DM, Wijdicks EF, Fulgham JR. Cerebral venous thrombosis complicated by hemorrhagic infarction: factors affecting the initiation and safety of anticoagulation. Cerebrovasc Dis. 1998 Jan-Feb; 8 (1):25-30
    View PubMed
  216. Liu Q, Weinshenker BG, Wingerchuk DM, Sommer SS. Denaturation fingerprinting: two related mutation detection methods especially advantageous for high G + C regions. Biotechniques. 1998 Jan; 24(1):140-7.
    View PubMed
  217. Wingerchuk DM, Krecke KN, Fulgham JR. Multifocal brain MRI artifacts secondary to embolic metal fragments. Neurology. 1997 Nov; 49 (5):1451-3
    View PubMed
  218. Wingerchuk DM, Noseworthy JH, Weinshenker BG. Clinical outcome measures and rating scales in multiple sclerosis trials. Mayo Clin Proc. 1997 Nov; 72 (11):1070-9
    View PubMed
  219. Weinshenker BG, Wingerchuk DM, Liu Q, Bissonet AS, Schaid DJ, Sommer SS. Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis. Neurology. 1997 Aug; 49 (2):378-85
    View PubMed
  220. Wingerchuk D, Liu Q, Wingerchuk D, Sobell J, Sommer S, Weinshenker BG. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology. 1997 Aug; 49 (2):626-8
    View PubMed
  221. Weinshenker BG, Hebrink D, Wingerchuk DM, Sommer SS, McMurray CT. Application of VAPSE-based analysis to genetic studies in MS. Mult Scler. 1997; 3:322.
  222. Scarr E, Wingerchuk DM, Juorio AV, Paterson IA. The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions. Neurochem Res. 1994 Feb; 19(2):153-9.
    View PubMed